
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio Inc. benefits from strong key opinion leader (KOL) sentiment surrounding its PAH treatment candidate, PROSERA, with expectations of a treatment effect size between 25m to 30m in 6-minute walk distance (6MWD), suggesting significant therapeutic efficacy. The company has demonstrated positive results from its phase 2 TORREY trial, highlighting consistent benefits across multiple endpoints, including pulmonary vascular resistance (PVR) reduction and pro-BNP reduction, while maintaining a favorable safety profile and durability. Increased investor interest has been noted following the recent Cantor conference, further indicating optimistic perspectives on Gossamer Bio's future prospects within its clinical pipeline.
Bears say
Gossamer Bio's stock outlook is negative primarily due to a perceived mispricing of the market's expectations regarding the success of its lead asset, Seralutinib, despite the recent increase in stock value. This mispricing suggests that investor sentiment may not accurately reflect the true risks and potential setbacks related to the company’s pipeline. Furthermore, a lack of clarity on the probabilities of success for its various clinical-stage products could contribute to continued volatility and uncertainty in financial performance.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares